• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Biogen receives breakthrough therapy designation for felzartamab, shares edge up

by October 9, 2024
written by October 9, 2024

Investing.com — Shares in Biogen (NASDAQ:BIIB) were trading marginally higher after the company said its investigational antibody felzartamab had received breakthrough therapy designation from US regulators as a treatment for late antibody-mediated rejection in kidney transplant patients.

In a statement on Tuesday, Massachusetts-based Biogen said the designation from the US Food and Drug Administration is given to drug candidates for serious or life-threatening conditions.

These medicine candidates have also shown preliminary evidence of providing substantial improvement over existing therapies, Biogen noted.

“Antibody-mediated rejection (AMR) is a major reason why kidney transplants fail, and currently patients suffering from AMR have tremendous unmet medical need,” said Travis Murdoch, Head of Biogen’s Human Immunology, or HI-Bio, unit.

“We are focused on tackling this important challenge, and the breakthrough therapy designation will enable us to work efficiently with the FDA to accelerate development of felzartamab in AMR.”

AMR is a disease where the immune system makes antibodies that damage transplanted organs.

Biogen said it plans to initiate late-stage trials for felzartamab across AMR and two other forms of kidney diseases in 2025. The treatment is still in an investigational phase, has not yet been approved by any regulatory authority, and its safety and effectiveness have not been established, Biogen flagged.

The announcements come after Biogen agreed to buy HI-Bio for up to $1.8 billion in May as part of a push to bolster its portfolio of rare disease medicines. The deal saw Biogen pay $1.15 billion in upfront costs and up to an additional $650 million if felzartamab hits certain development markers.

HI-Bio’s felzartamab has previously completed mid-stage studies for a type of kidney disease called primary membranous nephropathy, as well as AMR. The San Francisco-based group is also testing felzartamab in patients with IgA nephropathy, another version of chronic kidney disease.

(Reuters contributed reporting.)

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
What is the overall impact on Hurricane Milton on US stocks and sectors?
next post
Ratan Tata, chairman emeritus of India’s Tata conglomerate, in critical condition in hospital, sources say

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 5, 2025
    • This California startup is cleaning water and removing CO₂ from the atmosphere — all at a reduced cost

      June 5, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (504)
    • Stock (6,426)

    Latest News

    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

    Popular News

    • MGP Ingredients shares tumble 21% on weak preliminary Q3 results, lowered guidance
    • Canada faces pressure to hold election soon amid Trump tariff threat – Jefferies

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy